Navigation Links
PrimeraDx Appoints Albert A. Luderer to its Board of Directors
Date:9/22/2011

MANSFIELD, Mass., Sept. 22, 2011 /PRNewswire/ -- PrimeraDx today announced that Albert Luderer has been appointed to its Board of Directors.  

President and CEO Matthew McManus commented:  "We are excited to have Al join our board at this pivotal time.  We have just launched the ICEPlex System, which is the first molecular diagnostics system that is capable of high multiplex, multi-modal qPCR, and Al brings many years of experience in the commercialization of innovative products.  Al's established track record of commercializing diagnostic technologies will provide PrimeraDx with great strategic vision as we bring personalized medicine to the clinic."

Dr. Luderer has over 30 years of leadership experience in diagnostics, therapeutics and research tools companies.  He currently serves as CEO and Board Member at Integrated Diagnostics.  Dr. Luderer has served as President, CEO, and Director at BioTrove (acquired by Life Technologies), CEO and Director of Light Sciences Inc, President and COO at bioMerieux Inc, VP of R&D and Business Development at Dianon Systems (now Lab Corp), VP of Technology Development and Support at Boehringer Mannheim (now Roche), and Head of Biomedical Research for Ciba Corning.  Dr. Luderer earned a PhD from Rutgers University.

"I am very enthusiastic about PrimeraDx and the core technology behind the ICEPlex platform.  The ability to both run a high multiplex reaction and receive a quantitative result is very timely," Commented Dr. Luderer.  "I believe that PrimeraDx is positioned to lead the next generation of molecular diagnostics technology with their all-in-one well solution."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PrimeraDx Names Fayyaz Memon Vice President of Regulatory Affairs and Quality Assurance
2. Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
3. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Creabilis Appoints Dr David Roblin as Chief Medical Officer
6. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
9. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
10. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and ... previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on ...
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by ... biotechnology are now the fastest growing categories, finds ... Specialty Actives in Personal Care: Multi-regional Market Analysis ... and management consulting firm Kline. "Biotechnology ... that make them more effective for skin and ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
Breaking Biology Technology:
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
Breaking Biology News(10 mins):